The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | PROCEADE-CRC-01: an anti-CEACAM5 ADC for metastatic colorectal cancer
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents findings from the Phase I PROCEADE-CRC-01 trial (NCT05464030) of M9140, an anti-CEACAM5 antibody-drug conjugate (ADC), in metastatic colorectal cancer. Designed with an exatecan payload, this ADC showed promising results due to its stability and specific targeting of CEACAM5-expressing tumors. In the dose escalation study, administered intravenously every few weeks, dose-limiting toxicities were primarily hematological with no interstitial lung disease or ocular toxicity and only mild diarrhea and vomiting. Favorable pharmacokinetics demonstrated dose proportionality and low free exatecan levels in the bloodstream, with encouraging duration of treatment and progression-free survival (PFS) rates. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role – Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; AVEO; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Roche; Sanofi; Servier; Tachyon Therapeutics; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding – Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
